ViraTherapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 19
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $243M
Latest Deal Amount

ViraTherapeutics General Information

Description

Developer of next generation oncolytic viral therapy platform created for the treatment of cancer. The company develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Its proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. It also develops oncolytic cancer vaccines based on a chimeric virus derived from the Vesicular Stomatitis Virus (VSV), so called VSV-GP.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Boehringer Ingelheim
Primary Office
  • Exlgasse 20a
  • Innsbruck, 6020
  • Austria
+43 0512 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ViraTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 13-Sep-2018 $243M 00.000 00000 Completed Generating Revenue
5. Early Stage VC (Series B) 28-Oct-2016 00.000 00.000 Completed Generating Revenue
4. Early Stage VC (Series A) 24-Jun-2015 00.000 00.000 Completed Startup
3. Grant 01-Dec-2014 00.000 Completed Startup
2. Grant 01-Jul-2013 $13.2K Completed Startup
1. Angel (individual) 01-Apr-2013 Completed Startup
To view ViraTherapeutics’s complete valuation and funding history, request access »

ViraTherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of next generation oncolytic viral therapy platform created for the treatment of cancer. The company develops
Drug Discovery
Innsbruck, Austria
19 As of 2018
00.000
0000 0000-00-00
000000&0 00.000

0000000

or incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation u
0000 000000000
Houston, TX
00 As of 0000
000.00
000000000 - 000.00

00000000

ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labori
0000000000000
Oslo, Norway
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViraTherapeutics Competitors (78)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DNAtrix Venture Capital-Backed Houston, TX 00 000.00 000000000 - 000.00
00000000 Formerly VC-backed Oslo, Norway 00 000.00 000000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Corporation San Carlos, CA 000 00000 00000000 00000
0000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
You’re viewing 5 of 78 competitors. Get the full list »

ViraTherapeutics Patents

ViraTherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10265357-B2 Compositions, methods and uses for treating solid tumors using lcmv-gp-vsv pseudotype vectors Active 08-Oct-2008 0000000000
US-20140301992-A1 Compositions, methods and uses for treating solid tumors using lcmv-gp-vsv pseudotype vectors Granted 08-Oct-2008 0000000000 0
JP-2012504944-A Lcmv-gp pseudotyped vsv vector and tumor infiltrating virus producing cells for tumor therapy Granted 08-Oct-2008 000000000 0
CA-2739963-C Lcmv-gp-vsv pseudotyped vectors and tumor infiltrating virus-producing cells for the therapy of tumors Active 08-Oct-2008 000000000
EP-2350295-A1 Lcmv-gp-vsv-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors Granted 08-Oct-2008 C12N15/86

ViraTherapeutics Executive Team (4)

Name Title Board Seat Contact Info
Lisa Egerer Chief Operating Officer
Dorothee Holm-von Laer Co-Founder & Scientific Advisor
Ludwig Weiss Ph.D Co-Founder
Heinz Schwer Ph.D Chief Executive Officer
To view ViraTherapeutics’s complete executive team members history, request access »

ViraTherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViraTherapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Austria Wirtschaftsservice Venture Capital Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
CAST Gründungszentrum Accelerator/Incubator Minority 000 0000 000000 0
EMBL Ventures Venture Capital Minority 000 0000 000000 0
Empl Privatstiftung Other Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »